Our lead development candidates, MGX-001 and MGX-002, are novel formulations of a currently marketed pharmaceutical and different opioids for treatment of pain. Both candidates are expected to be the first products clinically proven to alleviate pain, while reducing unwanted side effects commonly associated with chronic opioid therapy. MGX-001 began Phase II proof-of-concept clinical trials in the second quarter of 2006. Our second pain product, MGX-002, is another novel formulation of a currently marketed product with a different opiate. Clinical trials for this product are planned to begin in 2007. Our third development product, MGX-006, uses a proprietary delivery technology with an agent that prevents and controls nausea and vomiting. MGX-006 is expected to initiate pivotal trials in 2007 under a 505(b)(2) pathway to approval.
| Product in Development | Description | Therapeutic Target | Anticipated Launch |
| MGX-006 | A novel delivery of a previously approved pharmaceutical | Treatment of nausea | 2008 |
| MGX-001 | A novel formulation of a currently marketed product plus morphine. | Treatment of chronic severe pain and a commonly associated opiate-induced side effect | 2009 |
| MGX-002 | A novel formulation of a currently marketed product plus another opiate. | Treatment of chronic severe pain and a commonly associated opiate-induced side effect | 2010 |
